Европейский союз - шведский - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - immunsuppressiva - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz kan ges som monoterapi vid intolerans mot metotrexat eller när fortsatt behandling med metotrexat är olämplig. adalimumab har visat sig minska risken för progression av ledskador mätt med röntgen och förbättra den fysiska funktionen, när det ges i kombination med metotrexat. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz kan ges som monoterapi vid intolerans mot metotrexat eller när fortsatt behandling med metotrexat är olämplig. adalimumab har inte studerats hos patienter yngre än 2 år. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab har visat sig minska risken för progression av perifer ledskada mätt med röntgen hos patienter med polyartikulär symmetrisk subtyper av sjukdomen och för att förbättra fysisk funktion. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.  paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Европейский союз - шведский - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiska medel - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Швеция - шведский - Läkemedelsverket (Medical Products Agency)

nordic group bv - metotrexatdinatrium - injektionsvätska, lösning i förfylld spruta - 10 mg - metotrexatdinatrium 11 mg aktiv substans - metotrexat

Швеция - шведский - Läkemedelsverket (Medical Products Agency)

nordic group bv - metotrexatdinatrium - injektionsvätska, lösning i förfylld spruta - 12,5 mg - metotrexatdinatrium 13,8 mg aktiv substans - metotrexat

Швеция - шведский - Läkemedelsverket (Medical Products Agency)

nordic group bv - metotrexatdinatrium - injektionsvätska, lösning i förfylld spruta - 15 mg - metotrexatdinatrium 16,5 mg aktiv substans - metotrexat

Швеция - шведский - Läkemedelsverket (Medical Products Agency)

nordic group bv - metotrexatdinatrium - injektionsvätska, lösning i förfylld spruta - 17,5 mg - metotrexatdinatrium 19,3 mg aktiv substans - metotrexat

Швеция - шведский - Läkemedelsverket (Medical Products Agency)

nordic group bv - metotrexatdinatrium - injektionsvätska, lösning i förfylld spruta - 20 mg - metotrexatdinatrium 22 mg aktiv substans - metotrexat

Швеция - шведский - Läkemedelsverket (Medical Products Agency)

nordic group bv - metotrexatdinatrium - injektionsvätska, lösning i förfylld spruta - 22,5 mg - metotrexatdinatrium 24,8 mg aktiv substans - metotrexat

Швеция - шведский - Läkemedelsverket (Medical Products Agency)

nordic group bv - metotrexatdinatrium - injektionsvätska, lösning i förfylld spruta - 25 mg - metotrexatdinatrium 27,5 mg aktiv substans - metotrexat

Швеция - шведский - Läkemedelsverket (Medical Products Agency)

nordic group bv - metotrexatdinatrium - injektionsvätska, lösning i förfylld spruta - 7,5 mg - metotrexatdinatrium 8,3 mg aktiv substans - metotrexat